Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.2%

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price traded down 1.2% on Monday . The stock traded as low as $750.53 and last traded at $751.26. 460,548 shares traded hands during trading, a decline of 85% from the average session volume of 3,031,165 shares. The stock had previously closed at $760.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LLY shares. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an "outperform" rating in a research note on Wednesday, May 1st. Erste Group Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research report on Thursday, April 11th. TheStreet raised shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a report on Friday, March 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

The firm has a market capitalization of $720.45 billion, a PE ratio of 111.67, a P/E/G ratio of 1.50 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The business's 50 day moving average is $761.48 and its two-hundred day moving average is $678.76.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The business's revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company's payout ratio is currently 76.58%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in shares of Eli Lilly and Company by 1.8% in the 1st quarter. Versant Capital Management Inc now owns 736 shares of the company's stock valued at $573,000 after buying an additional 13 shares in the last quarter. Moseley Investment Management Inc. boosted its stake in Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company's stock valued at $3,027,000 after acquiring an additional 14 shares in the last quarter. CGN Advisors LLC grew its holdings in Eli Lilly and Company by 1.4% in the first quarter. CGN Advisors LLC now owns 1,001 shares of the company's stock worth $779,000 after purchasing an additional 14 shares during the last quarter. Twin Peaks Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 2.0% during the 1st quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company's stock valued at $559,000 after purchasing an additional 14 shares during the last quarter. Finally, Pitti Group Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company's stock worth $1,271,000 after purchasing an additional 14 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.